Concepedia

Long-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial)

Robert J. Applegate, Manejeh Yaqub, James Hermiller, Poornima Sood, Shui Yu, Julie Doostzadeh, Jerome Williams, Naim Farhat, Ronald Caputo, Alexandra J. Lansky,

The American Journal of Cardiology · 2011 · 41 citations · 13 references

DOI

Concepts

References

13

Clinical End Points in Coronary Stent Trials

Donald E. Cutlip, Stephan Windecker, Roxana Mehran et al. · Circulation · 2007 · 5.4K citations

, , +13

Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent

Renu Virmani, Giulio Guagliumi, Andrew Farb et al. · Circulation · 2004 · 1.5K citations · Full text

, , +13

Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy

Eugène McFadden, Eugenio Stabile, Evelyn Regar et al. · The Lancet · 2004 · 1.4K citations

, , +16

Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease

Gregg W. Stone, Ali A. Rizvi, William Newman et al. · New England Journal of Medicine · 2010 · 896 citations · Full text

, , +15

Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial

Elvin Kedhi, Kaiyum Sheik Joesoef, Eugène McFadden et al. · The Lancet · 2010 · 687 citations

, , +9